These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38474182)

  • 41. Blocking of the High-Affinity Interaction-Synapse Between SARS-CoV-2 Spike and Human ACE2 Proteins Likely Requires Multiple High-Affinity Antibodies: An Immune Perspective.
    Khatri I; Staal FJT; van Dongen JJM
    Front Immunol; 2020; 11():570018. PubMed ID: 33042151
    [TBL] [Abstract][Full Text] [Related]  

  • 42. DNA aptamers inhibit SARS-CoV-2 spike-protein binding to hACE2 by an RBD- independent or dependent approach.
    Silwal AP; Thennakoon SKS; Arya SP; Postema RM; Jahan R; Phuoc CMT; Tan X
    Theranostics; 2022; 12(12):5522-5536. PubMed ID: 35910791
    [No Abstract]   [Full Text] [Related]  

  • 43. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
    Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
    J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Computational prediction of the effect of mutations in the receptor-binding domain on the interaction between SARS-CoV-2 and human ACE2.
    Celik I; Khan A; Dwivany FM; Fatimawali ; Wei DQ; Tallei TE
    Mol Divers; 2022 Dec; 26(6):3309-3324. PubMed ID: 35138508
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of SARS-CoV-2 pseudovirus invasion by ACE2 protecting and Spike neutralizing peptides: An alternative approach to COVID19 prevention and therapy.
    Chen J; Li S; Lei Z; Tang Q; Mo L; Zhao X; Xie F; Zi D; Tan J
    Int J Biol Sci; 2021; 17(11):2957-2969. PubMed ID: 34345219
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation.
    Rodriguez JA; Gonzalez J; Arboleda-Bustos CE; Mendoza N; Martinez C; Pinzon A
    Chem Biol Interact; 2022 Dec; 368():110244. PubMed ID: 36336003
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In silico investigation of critical binding pattern in SARS-CoV-2 spike protein with angiotensin-converting enzyme 2.
    Jafary F; Jafari S; Ganjalikhany MR
    Sci Rep; 2021 Mar; 11(1):6927. PubMed ID: 33767306
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An engineered nano-liposome-human ACE2 decoy neutralizes SARS-CoV-2 Spike protein-induced inflammation in both murine and human macrophages.
    Satta S; Meng Z; Hernandez R; Cavallero S; Zhou T; Hsiai TK; Zhou C
    Theranostics; 2022; 12(6):2639-2657. PubMed ID: 35401811
    [No Abstract]   [Full Text] [Related]  

  • 49. Emerging of composition variations of SARS-CoV-2 spike protein and human ACE2 contribute to the level of infection:
    AlGhamdi NA; Alsuwat HS; Borgio JF; AbdulAzeez S
    J Biomol Struct Dyn; 2022 Apr; 40(6):2635-2646. PubMed ID: 33138699
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of hACE2-interacting sites in SARS-CoV-2 spike receptor binding domain for antiviral drugs screening.
    Hu X; Cui J; Chen J; Du S; Wang X; Zhang Y; Qian J; Chen H; Wei F; Cai Q; Jia J; Wu J
    Virus Res; 2022 Nov; 321():198915. PubMed ID: 36084746
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Polymethoxyflavone from Citrus depressa as an inhibitor against various variants of SARS-CoV-2 spike protein.
    Liu TW; Hsu SJ; Hsieh YSY; Liu HK; Lee CK
    J Ethnopharmacol; 2024 Feb; 320():117412. PubMed ID: 37995824
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
    Xiang Y; Wang M; Chen H; Chen L
    Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
    [TBL] [Abstract][Full Text] [Related]  

  • 54. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
    Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
    J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ginkgolic acids inhibit SARS-CoV-2 and its variants by blocking the spike protein/ACE2 interplay.
    Xiang Y; Zhai G; Li Y; Wang M; Chen X; Wang R; Xie H; Zhang W; Ge G; Zhang Q; Xu Y; Caflisch A; Xu J; Chen H; Chen L
    Int J Biol Macromol; 2023 Jan; 226():780-792. PubMed ID: 36521705
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunoglobulin yolk targeting spike 1, receptor binding domain of spike glycoprotein and nucleocapsid of SARS-CoV-2 blocking RBD-ACE2 binding interaction.
    Eka Saputri M; Aisyah Rahmalia Effendi S; Nadila R; Azzam Fajar S; Damajanti Soejoedono R; Handharyani E; Nadia Poetri O
    Int Immunopharmacol; 2022 Nov; 112():109280. PubMed ID: 36183680
    [TBL] [Abstract][Full Text] [Related]  

  • 57. SARS-CoV-2 Variants Increase Kinetic Stability of Open Spike Conformations as an Evolutionary Strategy.
    Yang Z; Han Y; Ding S; Shi W; Zhou T; Finzi A; Kwong PD; Mothes W; Lu M
    mBio; 2021 Feb; 13(1):e0322721. PubMed ID: 35164561
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein.
    Jin H; Cheng L; Gong Y; Zhu Y; Chong H; Zhang Z; He Y
    J Virol; 2023 Aug; 97(8):e0019223. PubMed ID: 37578234
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Peimine inhibits variants of SARS-CoV-2 cell entry via blocking the interaction between viral spike protein and ACE2.
    Wang WJ; Chen Y; Su WC; Liu YY; Shen WJ; Chang WC; Huang ST; Lin CW; Wang YC; Yang CS; Hou MH; Chou YC; Wu YC; Wang SC; Hung MC
    J Food Biochem; 2022 Oct; 46(10):e14354. PubMed ID: 35894128
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Investigation on the interaction mechanism of different SARS-CoV-2 spike variants with hACE2: insights from molecular dynamics simulations.
    Wu J; Zhang HX; Zhang J
    Phys Chem Chem Phys; 2023 Jan; 25(3):2304-2319. PubMed ID: 36597957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.